Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA vaccine-AstraZeneca-COVID-19
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA vaccine-AstraZeneca-COVID-19 refers to a development program by AstraZeneca for next-generation COVID-19 vaccines utilizing a messenger RNA (mRNA) virus-like particle (VLP) platform. The program includes specific candidates such as AZD9838, which targets the SARS-CoV-2 Omicron BA.4/5 variants, and AZD6563, which targets the Omicron XBB.1.5 variant. These vaccines are designed to deliver mRNA encoding the viral spike protein, which is then expressed and assembled into VLPs within the body to trigger a robust immune response. This approach aims to combine the rapid development advantages of mRNA technology with the potentially enhanced immunogenicity and stability of VLP presentation. As of the ARTEMIS-C trial, these candidates are being evaluated in Phase I clinical studies for safety and immunogenicity as single-dose boosters in healthy adults.
- Other names
- SARS-CoV-2 mRNA-VLP vaccineSARS-CoV2 mRNA-VLP vaccineSARS-CoV 2 mRNA-VLP vaccineAstraZeneca mRNA COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on mRNA vaccine-AstraZeneca-COVID-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA vaccine-AstraZeneca-COVID-19.